According to the results of an international, randomised phase III clinical trial led by UPMC Hillman Cancer Center, immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma.
A new study has revealed that the side effects of the Pfizer-BioNTech jab against COVID-19 in 12-15-year-olds at high risk of complications from the infection are likely to be mild to moderate and clear up quickly because of certain coexisting conditions.
